AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
6,891.00GBp
4:47pm BST
6,891.00GBp
4:47pm BST
Change (% chg)
98.00 (+1.44%)
98.00 (+1.44%)
Prev Close
6,793.00
6,793.00
Open
6,830.00
6,830.00
Day's High
6,952.00
6,952.00
Day's Low
6,792.00
6,792.00
Volume
1,867,490
1,867,490
Avg. Vol
1,784,672
1,784,672
52-wk High
7,583.00
7,583.00
52-wk Low
5,312.00
5,312.00
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Mar '19 | 5,491.00 | 0.468 |
| FY 2018 | Dec '18 | 6,417.00 | 0.816 |
| Sep '18 | 5,340.00 | 0.340 | |
| Jun '18 | 5,155.00 | 0.276 | |
| Mar '18 | 5,178.00 | 0.268 | |
| FY 2017 | Dec '17 | 5,777.00 | 1.048 |
| Sep '17 | 6,232.00 | 0.541 | |
| Jun '17 | 5,051.00 | 0.376 | |
| Mar '17 | 5,405.00 | 0.424 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-19 | 11 | 5,995.25 | 6,276.00 | 5,827.45 | 6,114.09 |
| Quarter Ending Dec-19 | 11 | 6,551.50 | 6,896.53 | 6,073.73 | 6,503.50 |
| Year Ending Dec-19 | 26 | 23,574.70 | 24,226.70 | 22,085.00 | 23,766.70 |
| Year Ending Dec-20 | 26 | 26,044.00 | 28,328.00 | 24,249.40 | 26,023.40 |
| Earnings (per share) | |||||
| Quarter Ending Sep-19 | 8 | 0.97 | 1.12 | 0.83 | 0.98 |
| Quarter Ending Dec-19 | 8 | 1.03 | 1.24 | 0.88 | 1.15 |
| Year Ending Dec-19 | 27 | 3.58 | 4.16 | 3.37 | 3.90 |
| Year Ending Dec-20 | 26 | 4.25 | 4.97 | 3.57 | 4.73 |
| LT Growth Rate (%) | 5 | 15.11 | 17.53 | 13.00 | 9.56 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 46.78 | 29.73 | 33.85 | |
| P/E High - Last 5 Yrs. | 72.73 | 47.56 | 54.29 | |
| P/E Low - Last 5 Yrs. | 19.81 | 27.30 | 28.22 | |
| Beta | 0.96 | 1.00 | 0.99 | |
| Price to Sales (TTM) | 5.20 | 6.00 | 7.90 | |
| Price to Book (MRQ) | 10.75 | 3.84 | 4.38 | |
| Price to Tangible Book (MRQ) | -- | 4.14 | 5.07 | |
| Price to Cash Flow (TTM) | 19.38 | 21.62 | 23.70 | |
| % Owned Institutions | -- | 0.79 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.83 | 1.67 | |
| Dividend Yield - 5 Year Avg | 4.08 | 1.47 | 1.37 | |
| Dividend 5 Year Growth Rate | -0.39 | 6.74 | 6.82 | |
| Payout Ratio(TTM) | 144.68 | 50.64 | 46.67 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 6.04 | 13.42 | 14.65 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 0.74 | 6.45 | 8.45 | |
| Sales - 5 Yr. Growth Rate | -3.06 | 8.32 | 9.43 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 74.28 | 18.49 | 19.40 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -14.95 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -3.55 | 5.66 | 7.15 | |
| Capital Spending - 5 Yr. Growth Rate | -7.80 | 7.02 | 8.01 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.58 | 2.52 | 2.52 |
| Current Ratio (MRQ) | 0.75 | 3.55 | 3.52 |
| LT Debt to Equity (MRQ) | 170.36 | 11.64 | 12.61 |
| Total Debt to Equity (MRQ) | 205.84 | 16.17 | 17.64 |
| Interest Coverage (TTM) | 3.27 | 7.61 | 14.93 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 79.94 | 51.41 | 50.25 | |
| Gross Margin - 5 Yr. Avg. | 81.13 | 50.53 | 51.36 | |
| EBITD Margin (TTM) | 36.38 | -- | -- | |
| EBITD - 5 Yr. Avg | 30.18 | 17.64 | 16.42 | |
| Operating Margin (TTM) | 16.91 | -2.19 | -6.97 | |
| Operating Margin - 5 Yr. Avg. | 15.33 | 13.94 | 11.87 | |
| Pre-Tax Margin (TTM) | 10.61 | -2.50 | -7.30 | |
| Pre-Tax Margin - 5 Yr. Avg. | 10.17 | 18.73 | 15.72 | |
| Net Profit Margin (TTM) | 10.25 | -6.21 | -11.11 | |
| Net Profit Margin - 5 Yr. Avg. | 9.91 | 14.06 | 11.11 | |
| Effective Tax Rate (TTM) | 3.37 | 20.27 | 20.61 | |
| Effective Tax Rate - 5 Yr. Avg. | 2.63 | 22.92 | 24.51 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 284,744 | 1,012,949,194 | 870,638,159 | |
| Net Income/Employee (TTM) | 29,195 | 118,477,208 | 101,855,832 | |
| Receivable Turnover (TTM) | 4.17 | 5.61 | 5.88 | |
| Inventory Turnover (TTM) | 1.42 | 2.59 | 3.66 | |
| Asset Turnover (TTM) | 0.36 | 0.88 | 0.85 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 3.69 | 10.57 | 10.25 | |
| Return on Assets - 5 Yr. Avg. | 3.89 | 11.70 | 11.17 | |
| Return on Investment (TTM) | 5.42 | 13.04 | 12.69 | |
| Return on Investment - 5 Yr. Avg. | 5.39 | 14.80 | 14.15 | |
| Return on Equity (TTM) | 20.58 | 14.12 | 17.13 | |
| Return on Equity - 5 Yr. Avg. | 14.10 | 15.92 | 15.53 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -1.67 | -3.66 | -3.06 |
| EPS (TTM) % | -9.64 | -8.68 | -3.55 |
| Dividend % | 0.33 | -0.66 | -0.39 |
Note: Units in Millions of US Dollars
Performance for AstraZeneca PLC
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 7.25 | 5.51 | 99 | 47 |
| 13 Week | 19.15 | 17.67 | 99 | 34 |
| 26 Week | 28.56 | 16.96 | 99 | 15 |
| 52 Week | 19.13 | 21.68 | 99 | 66 |
| YTD | 17.57 | 4.77 | 99 | 20 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- London's FTSE 100 ends on a flat note, Sirius Minerals plunges
- UPDATE 2-London's FTSE 100 ends on a flat note, Sirius Minerals plunges
- With a backup to the backup, insulin makers say they're primed for Brexit
|
- UPDATE 1-AstraZeneca diabetes drug granted fast track status for heart failure treatment
- UPDATE 2-UK Stocks-Factors to watch on Sept 16
Institutional Holders
| % Shares Owned: | 54.01% |
| # of Holders: | 611 |
| Total Shares Held: | 708,526,563 |
| 3 Mo. Net Change: | -9,692,306 |
| # New Positions: | 18 |
| # Closed Positions: | 29 |
| # Increased Positions: | 162 |
| # Reduced Positions: | 162 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks